|| List of recent Leukocyte-related patents
| Genotoxicity as a biomarker for inflammation|
The invention provides a method for detection of inflammatory disease in a subject that comprises assaying a test sample of peripheral blood from the subject for a marker of dna damage. An elevated amount of marker present in the test sample compared to control sample is indicative of inflammatory disease activity, including sub-clinical inflammation.
| Method and material for separating leukocytes or mononuclear cells|
An object of the present invention is to provide a separation system and a separation material for efficiently separating white blood cells or mononuclear cells from a biological fluid containing blood cell components. White blood cells or mononuclear cells can be efficiently separated by contacting a biological fluid containing blood cell components with a separation material having an average fiber diameter of at least 2.0 μm but not more than 6.0 μm and an air permeability coefficient m of at least 6.2 but not more than 35 to capture white blood cells on the separation material, and recovering the captured white blood cells or mononuclear cells using a detachment solution..
| Apparatus and method for isolating leukocytes and tumor cells by filtration|
The present invention provides novel apparatuses and methods for isolating or recovering a subset of blood cells such as leukocytes and/or circulating tumor cells from blood samples by filtration without changing the intracellular concentration of a therapeutic agent such as an anticancer drug. Contrary to the art, the apparatuses and methods of the present invention advantageously provide cell lysates from recovered cells such as leukocytes and/or circulating tumor cells without substantial dilution of a therapeutic agent such as an anticancer drug..
|Method of detecting ethylated thymidine dna adducts|
A method of analyzing ethylated thymidine dna adducts is disclosed. The method comprises the steps of: providing leukocyte dna; adding at least one isotope-labeled internal standard and a plurality of enzymes to the leukocyte dna, and hydrolyzing the leukocyte dna into a plurality of nucleosides; using a solid-phase extraction column to extract the plurality of nucleosides; and using a stable isotope dilution nanoflow liquid chromatography-nanospray ionization tandem mass spectrometry to detect and quantify at least one ethylated thymidine dna adduct in the plurality of extracted nucleosides..
|Filtering unit having a calendered layer for removing leukocytes|
One aspect of the disclosure relates to a filtration unit intended to allow the removal of leukocytes from a fluid such as blood or a blood component, the unit containing a porous element including a medium for the removal of leukocytes by adsorption and filtration of the leukocytes. The disclosure also relates to a bag-based system including such a unit, said system being in particular arranged for the sterile and closed-circuit filtration of the fluid..
|Humanized transgenic mouse model|
This invention relates to a transgenic animal model for testing immunogenicity and protective efficacy of human vaccines and the method for generating such a multi-transgenic animal. This invention also relates to methods for screening compositions for human vaccine development.
|Pulmonary disease treatment and diagnosis based on arhgef1|
Treatment and diagnostic methods are provided for pulmonary disease, including chronic obstructive pulmonary disease, arhgef1, a leukocyte signaling molecule, functions normally to suppress integrin-mediated mmp production by alveolar macrophages. Mmp9 production by fibronectin-stimulated monocytes and macrophages depends on autocrine thromboxane receptor signaling and this signaling pathway is attenuated by arhgef1.
|Cytopheresis cartridges and use thereof|
The present invention relates to a cytopheretic cartridge for use in treating and/or preventing inflammatory conditions within a subject and to related methods. More particularly, the invention relates to a cytopheretic cartridge that includes a housing and, disposed within the housing, a solid support capable of sequestering activated leukocytes and/or platelets..
|Novel uses of elafin|
The invention relates to novel uses of the polypeptide elafin, and/or homologies, derivatives or fragments thereof having inhibitory activity against leukocyte elastase for the prevention and treatment of medical conditions like sirs.. .
|Novel leucocyte removal filter|
The present invention aims to provide a leukocyte depletion filter that has both higher leukocyte removal performance and higher blood permeability than conventional filters. The leukocyte depletion filter according to the present invention includes a filter material having an average fiber diameter of 0.30 to 1.60 μm and a coefficient of variation of fiber diameter of at least 0.40 but not more than 1.20..
|Reagents for reducing leukocyte interference in immunoassays|
Methods and devices for reducing interference from leukocytes in an analyte immunoassay are provided. In one embodiment, a method is provided comprising the steps of amending a biological sample such as a whole blood sample with one or more leukocidal reagents that reduce or eliminate the metabolic activity of leukocytes, and performing an immunoassay on the amended sample to determine the concentration of analyte in the sample.
|Biomarkers associated with nephropathy|
Use of urine biomarkers for diagnosing nephropathy, monitoring nephropathy progress, and assessing efficacy of a nephropathy treatment. These urine biomarkers include leukocyte-associated ig-like receptor-2, alpha-1 acid glycoprotein, their fragments, and combinations thereof..
|Plif multimeric peptides and uses thereof|
Provided is a multimeric peptide comprising at least two peptide monomers linked to one another, each of the at least two peptide monomers comprising at least 6 consecutive amino acids from the amino acid sequence as set forth in seq id no: 1, wherein the at least two peptide monomers are each no longer than 30 amino acids, wherein the multimeric peptide is capable of reducing binding of placenta immunomodulatory factor (plif) to human leukocytes.. .
|Antimicrobial peptides and derived metapeptides|
The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils.
|Agents for the molecular imaging of serine-protease in human pathologies|
The present invention is directed to the use of an irreversible ligand of a serine protease selected from the group consisting of leukocyte elastase, thrombin, tissue plasminogen activator (t-pa) and plasmin for the molecular imaging of said serine protease and the diagnosis of pathophysiological conditions associated with said serine protease activity.. .
|Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta|
Compounds that inhibit pi3kδ activity, including compounds that selectively inhibit pi3kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (pi3kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which pi3kδ plays a role in leukocyte function, using the compounds also are disclosed..
|Software integrated flow cytometric assay for quantification of the human polymorphonuclear leukocyte fcgammari receptor (cd64)|
A composition for evaluating a biological condition is disclosed. The composition has (a) a sample composition comprising at least one of: i.) a bodily specimen comprising a target moiety; ii.) a positive control moiety; and iii.) a negative control moiety; (b) an antibody composition comprising at least one of: i.) at least one target antibody; ii.) at least one positive control identifying antibody; and iii.) at least one negative control identifying antibody; and (c) at least one reference composition comprising at least one of: i.) a target signal reference composition; and ii.) a reference identifier composition..
|Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy|
Methods are provided for the prevention and treatment of seizures and epilepsy. It is shown herein that leukocyte recruitment plays a key role in the pathogenesis of epilepsy.
|Activated leukocyte conditioned supernatant and uses for wound healing|
Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.. .
|Humanized transgenic mouse model|
Provided is a transgenic animal model for testing immunogenicity and protective efficacy of human vaccines and the method for generating such a multitransgenic animal. Also disclosed are methods for screening compositions for human vaccine development.
|Formulations and methods of treatment of skin conditions|
A liquid or ointment formulation for the treatment of a skin condition associated with leukocyte accumulation in the skin includes a therapeutic compound selected to reduce leukocyte accumulation in the skin and an aqueous solution of an organic solvent. The organic solvent increases skin permeability.
|Methods and compositions for diagnosis and prognosis of renal injury and renal failure in a non-surgical icu population|
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects admitted to a hospital critical care setting for other than a post-surgical or trauma indication. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of insulin-like growth factor ia, soluble epidermal growth factor receptor, and leukocyte elastase as diagnostic and prognostic biomarkers in renal injuries..
|Stabilized leukocytes and their use in hiv-diagnosis and therapy|
A method of producing extremely stable leukocytes from human blood samples which are stable for long period of time under extraordinary temperature conditions. The method also relates to producing and stabilizing the leukocytes with formaldehyde release agents.
|Inhibition of lar phosphatase to enhance therapeutic angiogenesis|
The present invention relates to the regulation of angiogenesis and arteriogenesis by leukocyte antigen-related protein tyrosine phosphatase (lar). The invention further relates to the use of inhibitors of lar expression and/or activity to stimulate angiogenesis and/or arteriogenesis..
|Prognostic test of the progression of a solid tumour by image analysis|
The present invention relates to a method for the prognosis of the progression of a solid tumour in a patient, which includes at least the following steps: a) making, from a tumour sample, a virtual slide on which a tumour front can be identified; b) quantifying, on said virtual slide made in step a), the density of cells and/or blood vessels present in a continuous area covering the tumour front and extending on either side of the tumour front over a distance of at least 0.5 mm, referred to as the quantification area; and c) deducing, from said quantification, the risks of postoperative relapse and/or the sensitivity to various antitumor treatments and/or the risks of developing metastases in said patient. Preferably, the cells to be quantified are leukocytes, such as t cells, b cells, macrophages, natural killer cells, dendritic cells, or subpopulations of these immune system cells..
|Microfluidic assay in idealized microvascular network for characterization of leukocyte adhesion cascade|
Methods of assaying the leukocyte adhesion cascade (lac) and monitoring leukocyte rolling, adhesion, and/or migration can be implemented with an apparatus that includes an idealized microvascular network (imn) of one or more interconnected idealized flow channels in fluid communication through a porous wall with a tissue space (e.g., idealized tissue space). The methods of assaying the lac can be implemented with means for quantifying modulation of the leukocyte adhesion cascade.
|Compositions and methods for leukocyte-targeting multi-valent imaging probes|
The present application discloses a new multivalent peptide ligand specifically targeting polymorphonuclear leukocytes (pmns) with favorable pharmacological parameters to monitor sites of inflammation for imaging. The detailed synthesis, characterization, and pharmacological evaluation of the ligands are reported here.